Drug Trial Radar · NCT07716449
QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
560
Planned (sponsor's estimate)
Start
Sep 24, 2026
Primary completion
Sep 2028
Study completion Aug 2029
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, open, multicenter phase III clinical study designed to compare the efficacy and safety of QLS31905 injection combined with CAPOX versus sintilimab combined with CAPOX in the first-line treatment of CLDN18.2 positive, PD-L1 CPS \< 5 , Her-2 Negtive unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma
Interventions
QLS31905Drug
QLS31905 will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.
SintilimabDrug
Sintilimab will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.
OxaliplatinDrug
Oxaliplatin will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.
CapecitabineDrug
Capecitabine will be administered orally twice daily (bid).
Primary outcomes
What the sponsor says the trial is designed to measure.
- OSTime frame: Up to 44 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.